| European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia A Hochhaus, M Baccarani, RT Silver, C Schiffer, JF Apperley, F Cervantes, ... Leukemia 34 (4), 966-984, 2020 | 1308 | 2020 |
| Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial S Saussele, J Richter, J Guilhot, FX Gruber, H Hjorth-Hansen, A Almeida, ... The Lancet Oncology 19 (6), 747-757, 2018 | 558 | 2018 |
| Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin B Pang, X Qiao, L Janssen, A Velds, T Groothuis, R Kerkhoven, ... Nature communications 4 (1), 1908, 2013 | 448 | 2013 |
| Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up A Hochhaus, S Saussele, G Rosti, FX Mahon, JJWM Janssen, ... Annals of Oncology 28, iv41-iv51, 2017 | 403 | 2017 |
| Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure TP Hughes, MJ Mauro, JE Cortes, H Minami, D Rea, DJ DeAngelo, ... New England Journal of Medicine 381 (24), 2315-2326, 2019 | 370 | 2019 |
| Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up M Heuser, Y Ofran, N Boissel, SB Mauri, C Craddock, J Janssen, ... Annals of Oncology 31 (6), 697-712, 2020 | 237 | 2020 |
| Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia … F Baron, M Labopin, D Niederwieser, S Vigouroux, JJ Cornelissen, ... Leukemia 26 (12), 2462-2468, 2012 | 234 | 2012 |
| Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial E Kneppers, B van der Holt, MJ Kersten, S Zweegman, E Meijer, G Huls, ... Blood, The Journal of the American Society of Hematology 118 (9), 2413-2419, 2011 | 222 | 2011 |
| Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40–60 years JJ Cornelissen, J Versluis, JR Passweg, WLJ Van Putten, MG Manz, ... Leukemia 29 (5), 1041-1050, 2015 | 156 | 2015 |
| High INDO (indoleamine 2, 3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome M Chamuleau, A van de Loosdrecht, C Hess, J Janssen, A Zevenbergen, ... haematologica 93 (12), 1894-1898, 2008 | 132 | 2008 |
| Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study HM Lokhorst, B van der Holt, JJ Cornelissen, MJ Kersten, M van Oers, ... Blood, The Journal of the American Society of Hematology 119 (26), 6219-6225, 2012 | 122 | 2012 |
| Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: A randomised trial of the Dutch–Belgian Cooperative Trial for … N Thielen, B van der Holt, JJ Cornelissen, GEG Verhoef, T Gussinklo, ... European journal of cancer 49 (15), 3242-3246, 2013 | 90 | 2013 |
| Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors A Hochhaus, M Breccia, G Saglio, V García-Gutiérrez, D Réa, J Janssen, ... Leukemia 34 (6), 1495-1502, 2020 | 88 | 2020 |
| Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients (Pts) with very high/high-risk myelodysplastic syndrome (vHR/HR-MDS … AM Brunner, J Esteve, K Porkka, S Knapper, E Traer, S Scholl, ... Blood 138, 244, 2021 | 85 | 2021 |
| Cessation of tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients with deep molecular response: results of the Euro-Ski trial F Mahon, J Richter, J Guilhot, H Hjorth-Hansen, A Almeida, ... Blood 128 (22), 787, 2016 | 84 | 2016 |
| Phase Ib study of the anti-TIM-3 antibody MBG453 in combination with decitabine in patients with high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) U Borate, J Esteve, K Porkka, S Knapper, N Vey, S Scholl, ... Blood 134, 570, 2019 | 83 | 2019 |
| Nutritional support in patients with GVHD of the digestive tract: state of the art BS Van der Meij, P De Graaf, NJ Wierdsma, JAE Langius, J Janssen, ... Bone marrow transplantation 48 (4), 474-482, 2013 | 83 | 2013 |
| Biomarker profiling of steroid-resistant acute GVHD in patients after infusion of mesenchymal stromal cells LCJ te Boome, C Mansilla, LE van der Wagen, CA Lindemans, ... Leukemia 29 (9), 1839-1846, 2015 | 82 | 2015 |
| Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia GJ Ossenkoppele, JJWM Janssen, AA van de Loosdrecht Haematologica 101 (1), 20, 2016 | 80 | 2016 |
| EURO-SKI investigators. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective … S Saussele, J Richter, J Guilhot, FX Gruber, H Hjorth-Hansen, A Almeida, ... Lancet Oncol 19 (6), 747-757, 2018 | 78 | 2018 |
